CREATE RISK PREDICTION MODELING AND DRUG WITHDRAW ROAD MAP THROUGH PATTERN EXTRACTION AND DATA MINING: A MASTER ALGORITHM DEVELOPMENT FROM THE SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Yan Zhao1, Li Xiaomei2, Rong Mu3, Hua Wei3, Lingi Dong4, Xiaoxia Zuo5, Li Shouxin6, Hongsheng Sun7, Guanmin Gao8, Li jun Wu9, Hui Xiao10, Yuhua Jia10, Fei Vie10, SSDM Collaboration Group, China.

Background: Combination therapy with DMARDs for treating RA is standard of care. However, certain rates of adverse events (AEs) are unavoidable. The stigmas are how to predict the risk and how to define drug withdraw strategy in reduction of AEs are developed, which are expendable and replicatable. Via continuing data inputs and machine learning, an artificial intelligent system in assisting clinical forecast and decision-making may be achieved with SSDM.

Methods: SSDM is an interactive mobile disease management tool, including two application systems (APPs) for both the doctors and the patients. The patients can input medical records (including medication and laboratory test results) and perform self-evaluation (DAS28, HAQ) via the application. The data synchronizes to mobiles of authorized rheumatologists via Wi-Fi, and advices could be delivered. In previous studies, we demonstrated that patients could master SSDM after training.

Results: From Jun 2014 to Jan 2019, 44,533 RA patients from 587 centers registered in SSDM. 135 different drugs and 882 combination therapies are identified. LP happens at 317 and IP at 286, ALT at 322 cases in 641 treatment regiments. Among them, MTX based regiments are 257 types, and the risk ratio (RR) are profiled as predication model by comparing each AE rate of combination regimen with that of MTX monotherapy (Fig 1). The RR ranges from 0.28 to 6.28. The highest risk combination of prednisone (Pred), leflunomide (LEF), methotrexate (MTX), hydroxychloroquine (HCO) and Celecoxib is selected (RR=6.28) to develop a master algorithm. Figure 2 shows Bayesian network, in which, quartet correlates with 31 different regiments. Based on Bayesian method, the probabilities of LP, IP and ALT are plotted through 64 modeling, and the algorithm for drug withdrawals strategies is generated. Drug withdrawing sequence for LP is HCO, then Celi, then LEF, then Pred, the risks of LP are reduced by 41%, 22% 36% and 15%, respectively. For IP, withdrawing sequence is Pred, then LEF, then Celi, then HCO, the risks of IP are reduced by 45%, 28%, 23% and 4%, respectively. For ALT, withdrawing sequence is MTX, then Pred, LEF, then Celi, the risks of ALT are reduced by 48%, 8%, 7%and 6%.

Conclusion: Through patterns extraction, data mining, modeling, and Bayesian networking, a risk prediction model and a master algorithm for drug withdrawal strategy in reduction of AEs are developed, which are expendable and replicatable. Via continuing data inputs and machine learning, an artificial intelligent system in assisting clinical forecast and decision-making may be achieved with SSDM.

Disclosure of Interests: None declared


Figure 1

Figure 2
Rheumatoid arthritis — biological DMARDs

SAT0120
COMPARATIVE EFFECTIVENESS OF TOFACITINIB AND TNF INHIBITORS SINCE 2014. IMPACT OF COMBINATION WITH METHOTREXATE

Denis Choquette1, Louis Bessette2, Loïc Choquette Sauvageau1, Isabelle Ferdinand3, Paul Harauzi1, Frédéric Massicotte4, Jean-Pierre Pelletier1, Jean-Pierre Raynauld5, Marie-Anaïs Rémillard1, Diane Sauvageau1, Édith Villeneuve1, Louis Coupal1
1Institut de Recherche en Rhumatologie de Montréal (IRRIM), Rhumatologie, Montréal, Canada; 2Centre de l’Ostéoponrose et de Rhumatologie de Montréal (CORQ), Montréal, Canada; 3Center de l’Ostéoponrose et de Rhumatologie de Québec (CORQ), Québec, Canada

Background: Tofacitinib (TOFA), a targeted synthetic DMARD, has been approved for the treatment of rheumatoid arthritis (RA) in Canada since April 2014. This oral agent preferentially inhibits signalling by cytokine receptors associated with JAK1 and JAK3 subunits. It is also indicated for the treatment of PsA and UC since October 2018. Clinical experience with this molecule has been increasing, and questions relating to its efficacy and long-term safety are of interest. Data collection through RHUMADATA®, a Quebec based clinical database and registry, allows comparison of new options with more traditional agents such as tumor necrosis factor inhibitors (TNFi).

Objectives: The current analysis compares TOFA to TNFi used with and without methotrexate (MTX) among patients with RA.

Methods: Data collected since January 1, 2014 (when TOFA became available in Canada) at the Institut de Recherche en Rhumatologie de Montréal (IRRIM) and the Centre de l’Ostéoponrose et de Rhumatologie de Québec (CORQ) was extracted from RHUMADATA® on January 7, 2019. Patients initiated on TOFA or a TNFi (adalimumab, certolizumab, etanercept, infliximab, mAb) (without or with MTX were selected. Data include baseline characteristics (socio-demographic variables, concomitant and past medication, comorbidities and the Charlson comorbidity index (CCI)), variables measured over time (lab results, patient and physician-reported outcomes, and disease activity measures) and persistence data (treatment duration, reason for cessation). The groups were compared to identify potential confounders, and persistence data were analyzed using Kaplan-Meier and Cox methods.

Results: A total of 480 patients were prescribed TOFA (n=162) or a TNFi (n=318) since January 1, 2014. Of those, 57% (n=92) and 70% (n=224) were treated with MTX in the TOFA and TNFi group respectively and mean disease duration was 12.1 (standard deviation=11.0) and 7.2 (8.1) years. TOFA and TNFi represent the first treatment following csDMARD-IR for 33%(TOFA) and 62%(TNFi). In the TOFA group, 84% were women, 15% were smokers and the mean age at treatment initiation was 57.7 (11.5) years. In the TNFi group, 77% were women, 12% were smokers and the mean age at treatment initiation was 54.2 (13.7) years. At treatment initiation, patient global, pain and fatigue assessments, made on a visual analog scale ranging from 1 to 10 (TOFA=5.6 (2.5), 5.9 (2.7) and 5.7 (2.9) in the TOFA group and 5.0 (2.9), 5.5 (3.0) and 5.1 (3.1) in the TNFi group. Baseline disease activity was assessed as moderate or high/severe in 85.9% and 76.7% of TOFA (?) patients (DAS28(4)-ESR criteria). Among the 56 (35%) TOFA and 146 (46%) TNFi patients ceasing therapy, reasons for cessation were “ineффicacy” (TOFA: 64% vs TNFi: 56%) and “adverse events” (TOFA: 16% vs TNFi: 11%). Patients remaining on TOFA and TNFi therapy at last follow-up had an average treatment duration of 1.7 (1.1) and 2.7 (1.5) years and no difference in retention was observed between TOFA and TNFi treated patients (log-rank p=0.41).

Patients treated with a TNFi in combination with MTX had better treatment retention than those treated without MTX (log-rank p=0.04) while patients treated with TOFA/MTX had similar retention (log-rank p=0.96). These results remain unchanged when adjusted for gender, age at treatment initiation, disease duration, and comorbidities.

Conclusion: In our real-world data registry, treatment with TNFi and TOFA yielded similar retention over time. Subjects treated with TNFi and MTX remained on treatment longer than those treated without MTX while subjects treated with tofacitinib with or without MTX had similar retention.

Disclosure of Interests: Denis Choquette Grant/research support from: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Consultant for: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Louis Bessette Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Sandoz, Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, Speakers bureau: Pfizer, Frédéric Massicotte Consultant for: AbbVie, Pfizer, Janssen, Eli Lilly, Speakers bureau: Janssen, Jean-Pierre Pelletier Shareholder of: Shareholder in ArthroLab Inc., Grant/research support from: Study funded by TRB Chemedica SA, Consultant for: TRB Chemedica SA, Jean-Pierre Raynauld Consultant for: ArthroLab Inc., Marie-Anaïs Rémillard Consultant for: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Paid instructor for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Diane Sauvageau: None declared, Édith Villeneuve Consultant for: AbbVie, UCB, Celgene, Roche, Pfizer, Amgen, Sanofi-Genzyme, Paid instructor for: AbbVie, Speakers bureau: AbbVie, Pfizer, CMS, Roche, Louis Coupal: None declared


SAT0121
EFFECT OF SARILUMAB ON GLYCOXSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES

Mark C. Genovese1, Gerd Rüdiger Burmester2, Owen Hagingo3, Hubert van Hoogstraten4, Erin Mangart5, Karthinnathan Thangavee6, Roy Fleischmann7, Thomas Mandrup-Poulsen8, 9Stanford University Medical Center, Palo Alto, CA; 10United States of America; 11Charité University Medicine, Berlin, Germany; 12Sanofi Genzyme, Bridgewater, NJ; 13United States of America; 14Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America; 15Sanofi Genzyme, Boston, MA; 16United States of America; 17Metropole Clinical Research Centre, Dallas, TX, United States of America; 18University of Copenhagen, Copenhagen, Denmark

Background: Sarilumab is a human mAb blocking the IL-6Rα, approved for adult patients with moderately to severely active RA. The incidence of Type 2 diabetes (T2D) increased in patients with RA, and elevated IL-6 may be an independent risk factor.

Objectives: We conducted a post hoc analysis into the effect of sarilumab treatment on glycated hemoglobin (HbA1c) levels.

Methods: TARGET (NCT01709578) was a 24-week study of sarilumab 150/200 mg q2w vs placebo (all +csDMARD) in TNFi-inadequate response/intolerant (IR/INT) patients. MONARCH (NCT0232690) was a 24-week monotherapy study of sarilumab 200 mg q2w vs adalimumab 40 mg q2w in TNFi-INT/IR, bDMARD-naive patients. There were 78/546 (14.3%) and 28/369 (7.6%) diabetic patients per ADA criteria (baseline fasting glucose ≥7 mmol/L or baseline HbA1c ≥6.5%) in TARGET and MONARCH, respectively.

Results: In patients with RA and diabetes, the decrease in HbA1c at Week 24 was greater in sarilumab-treated groups than placebo (TARGET; in combination with csDMARDs) or adalimumab (MONARCH; monotherapy) groups (Figure). There was no interaction between change in HbA1c and corticosteroid use nor were changes in HbA1c correlated with changes in CRP, DAS28-CRP, or hemoglobin level. Among sarilumab-treated patients, those with baseline IL-6 >37.5 pg/mL (>3× upper limit of normal) had greater reductions in HbA1c (least squares mean change -0.27) than those with baseline IL-6 levels ≤37.5 pg/mL (least squares mean change -0.11). Sarilumab safety profile was similar in diabetic vs non-diabetic patients with RA.

Conclusion: Patients with RA and diabetes treated with sarilumab had greater improvements in HbA1c than those treated with adalimumab or placebo. With monotherapy, differences between sarilumab and